News

The company said that $30,000 grant has been awarded to Globe Laboratories, the licensor of the technology for this year and can be increased upon completion of preliminary

FDA’s decision is supported by the identification of deficiencies in the conduct and design of the bioequivalence study which was submitted by the company in support of Pseudoephedrine

As per the terms of the offer, Elanco would acquire products, manufacturing licenses, distribution rights and the existing contract portfolio, as well as the related intellectual property and

Upon recruitment, patients will be placed in one of four dose-escalating cohorts. Following completion of the dose escalation phase, the trial plan calls for a stable-dose phase in

The tie up will enable MEDecision to help its healthcare payer and provider customers transition to, comply with and capitalize on the industry’s forthcoming ICD-10 requirements. As per

Halozyme has posted net loss of $16.89m, compared to a net loss of $12.66m, for the same period in 2009. The company’s operating loss was $17.88m for the

Nectar Lifesciences is a research driven pharmaceutical organization, engaged in manufacturing and delivering pharmaceutical products. Nectar Lifesciences CEO and director said the Japanese audit is one of the

The company’s loss from operations was $14.45m for the full year ended 31 December 2010, compared to $78.94m for the same period in 2009. Affymax has generated net

In the first part, Biotron has dosed around 12 patients in the center, dddmag.com reported. Patients were divided according to the dosing of the drug, in which one-third